Experience with cladribine tablets for highly active multiple sclerosis in real clinical practice
https://doi.org/10.14412/2074-2711-2022-1-22-25
Abstract
Objective: to evaluate the efficacy and safety of cladribine tablets as a treatment for immune reconstitution of highly active multiple sclerosis (HAMS) in general clinical practice.
Patients and methods. 34 patients with HAMS who were followed up at the Moscow Multiple Sclerosis Center in 2018–2021 received two full treatment courses. HAMS diagnosis was established in the presence of two or more exacerbations per year without treatment or one exacerbation in patients receiving pathogenetic treatment in the presence of concomitant manifestations of the activity of the pathological process on MRI. Before initiation of cladribine therapy, the median exacerbation rate was 2.3 per year, i.e., 34 patients per year had a total of 78 exacerbations.
Results and discussion. Only two clinical exacerbations were registered (one each in the first and second year) during two years of treatment among all 34 patients, the average frequency of exacerbations was 0.05 per year; in three cases, a subclinical exacerbation was noted - new Gd+ lesions on T2-weighted images on MRI, the total number of events was 0.15 per year. No significant adverse events were reported.
Conclusion. Cladribine tablets are a highly effective and safe treatment option for HAMS.
About the Authors
S. V. Petrov
Moscow Multiple Sclerosis Center
Russian Federation
Russian Federation
7, Skaryatinsky Lane, Moscow 121069
O. V. Boyko
Moscow Multiple Sclerosis Center;
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia;
Institute of clinical neurology, Federal Center of Brain and Neurotechnologies, FMBA of Russia
Russian Federation
Russian Federation
7, Skaryatinsky Lane, Moscow 121069;
Department of Neurology, Neurosurgery, and Medical Genetics, 1, Ostrovityanov St., Moscow 117997;
1, Ostrovityanov St., Build 10, Moscow 117997
A. N. Boyko
Moscow Multiple Sclerosis Center;
Department of Neurology, Neurosurgery, and Medical Genetics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia;
Institute of clinical neurology, Federal Center of Brain and Neurotechnologies, FMBA of Russia
Russian Federation
Russian Federation
7, Skaryatinsky Lane, Moscow 121069;
Department of Neurology, Neurosurgery, and Medical Genetics, 1, Ostrovityanov St., Moscow 117997;
1, Ostrovityanov St., Build 10, Moscow 117997
References
1. Dobson R, Giovannoni G. Multiple sclerosis – a review. Eur J Neurol. 2019 Jan;26(1):27-40. doi: 10.1111/ene.13819. Epub 2018 Nov 18.
2. Gusev EI, Boyko AN. Rasseyannyy skleroz. Nauchno-prakticheskoye rukovodstvo v dvukh tomakh [Multiple sclerosis. Scientific a nd practical guide in two volumes]. Moscow: ROOI «Zdorov'ye cheloveka»; 2021. Vol. 2. P. 97-113 (In Russ.).
3. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010 Jul;133(Pt 7):1900-13. doi: 10.1093/brain/awq076. Epub 2010 Apr 27.
4. Diaz C, Zarco L, Rivera DM. Highly active multiple sclerosis: An update. Mult Scler Relat Disord. 2019 May;30:215-24. doi: 10.1016/j.msard.2019.01.039. Epub 2019 Jan 24.
5. Gusev EI, Boyko AN. Rasseyannyy skleroz. Nauchno-prakticheskoye rukovodstvo v dvukh tomakh [Multiple sclerosis. Scientific and practical guide in two volumes]. Moscow: ROOI «Zdorov'ye cheloveka»; 2021. Vol. 2. P. 224-36 (In Russ.).
6. Jacobs BM, Ammoscato F, Giovannoni G, et al. Cladribine: mechanisms and mysteries in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1266-71. doi: 10.1136/jnnp-2017-317411
7. Karussis D, Petrou P. Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale. Immunol Res. 2018 Dec;66(6):642- 8. doi: 10.1007/s12026-018-9032-5
8. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet. 1992 Oct 17;340(8825):952-6. doi: 10.1016/0140-6736(92)92826-2
9. Leist TP, Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr Med Res Opin. 2007 Nov;23(11):2667-76. doi: 10.1185/030079907x233142
10. Yildiz O, Mao Z, Adams A, et al. Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine. Mult Scler Relat Disord. 2018 Aug;24:20-7. doi: 10.1016/j.msard.2018.05.010. Epub 2018 Jun 1.
11. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20.
12. Deeks ED. Cladribine Tablets: A Review in Relapsing MS. CNS Drugs. 2018 Aug;32(8):785-96. doi: 10.1007/s40263-018-0562-0
13. Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler. 2018 Oct;24(12):1594-604. doi: 10.1177/1352458517727603. Epub 2017 Sep 5. 1
14. Warnke C, Leussink VI, Goebels N, et al. Cladribine as a therapeutic option in multiple sclerosis. Clin Immunol. 2012 Jan;142(1):68-75. doi: 10.1016/j.clim.2011.05.009. Epub 2011 Jun 1.
15. Boyko AN, Boyko OV. Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis. Degener Neurol Neuromuscul Dis. 2018 May 3;8:35-44. doi: 10.2147/DNND.S161450
Review
For citations:
Petrov S.V., Boyko O.V., Boyko A.N. Experience with cladribine tablets for highly active multiple sclerosis in real clinical practice. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1):22-25. (In Russ.) https://doi.org/10.14412/2074-2711-2022-1-22-25
Views: 275
Email this article 